NCT06542874

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 448 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Conditions

• Type 2 Diabetes (T2D)

Interventions

Type	Name	Description
DRUG	NNC0487-0111 subcutanous	NNC0487-0111 administered subcutanously (under the skin)
DRUG	Placebo (NNC0487-0111 subcutanous)	NNC0487-0111 placebo administered subcutanously (under the skin)
DRUG	NNC0487-0111 oral	NNC0487-0111 administered orally (in the mouth)
DRUG	Placebo (NNC0487-0111 oral)	NNC0487-0111 placebo administered orally (in the mouth)

Timeline

• Start date: 2024-08-07
• Primary completion: 2025-10-01
• Completion: 2025-10-24
• First posted: 2024-08-07
• Last updated: 2025-12-29

Locations

119 sites across 11 countries: United States, Bulgaria, Croatia, Germany, Greece, Hungary, Japan, Poland, Romania, Slovakia, Spain

Regulatory

• FDA-regulated drug study